As an expert in medical devices for the treatment of cerebrovascular disease, Balt is at the cutting-edge when it comes to technology thanks to its full control of the development and production processes. Balt offers the world’s widest range of products for the treatment of both ischemic and hemorrhagic stroke (aneurysms, arteriovenous malformations, etc.). For example, Balt makes a stent for mechanical thrombectomy in acute stroke while at the same time Balt offers a variety of other devices, including stents, coils, microcatheters, microguides, balloons and liquid embolics. Balt is recognized in its field for its great capacity for innovation. For this reason the company devotes 10% of its budget to research and development, as compared to a 5% average in the MedTech sector, and works in close collaboration with specialists and hospitals in order to create its products.
Balt’s products are recognized for their innovative qualities and their excellence. The technicians who produce Balt’s medical devices are known for their meticulous attention to detail. No traditional training exists for what they do, so everything is taught by Balt. Our technicians have a variety of professional and training backgrounds, and they often have worked in jobs requiring a high level of precision. They receive their training at Balt over a period of many months before becoming operational. In fact, dozens of different steps are required to manufacture our products, which are often made up of parts thinner in diameter than a single strand of hair.
Sandie Sudrot, operating technician
As a company, we pride ourselves on our ability to innovate with a forward looking mindset. This enables us to provide physicians with products that fulfill their specific needs and in doing so to find strategic, innovative, technological solutions for the medical community working in the neurovascular field. Several types of innovations exist that directly involve medical devices :
• Product-based innovation
• Innovations based on manufacturing processes
• Innovations based on practices and therapies
Balt is constantly working on breakthrough innovations that aim to introduce new and spectacular features to its products. In parallel we also work on incremental innovations that enable us to significantly improve existing products and procedures over time.
One of the keys to the success of innovation in the medical field requires concentrating first and foremost on the needs of the physicians who use our products. In our field, physicians are not only a source of information on their own specific needs, but also quite often are co-innovators, with the ability to identify the solution to their needs. An early example of this is in 1987, a well-known Professor, in partnership with Balt, developed the first microcatheter for the treatment of arteriovenous malformations.
At Balt, new product R&D is one of our main activities. We know that the degree of contact with our clinical environment, and especially with teaching hospitals, is directly correlated with the degree of technological innovation inherent to the products we strive to develop.
At Balt, we benefit from a legacy that has made it possible for us to be involved in the evolution of neuroendovascular therapy since its beginnings. Innovation in our company has always been guided mainly by the physician users. In order to improve over time, and to expand our range of cutting-edge products, our R&D is based on the following three pillars :
• Listening to medical professionals in order to provide them with the most appropriate solutions
• Developing breakthrough products (new materials, new procedures, etc.), constantly improving existing products, and developing new product lines
• Creating one-time partnerships with innovative start-ups
It is through all this that we are also able to develop new therapies for treating certain diseases for which few treatments exist to date, such as chronic subdural hematoma (cSDH). Finally, since innovation is essential to Balt’s corporate culture, the “Balt incubator” was created in 2017, in order to support start-ups with cutting-edge technologies in the medical device sector.
For many years, the company has conducted international clinical studies on its leading medical devices. In keeping with this, two studies were launched recently, one studying the Balt coils used in the treatment of aneurysms, and another investigating Balt’s liquid embolic used to treat arteriovenous malformations. Balt is also preparing future studies in order to generate new clinical and quality of life data.
Driven by an unceasing desire to improve understanding of the clinical benefit of its products, Balt places clinical development at the heart of its strategy.
Last modification: 4 November 2019